Floatz logo

Favid Active Immunotherapy

Lymphoma, Low-Grade

FavrillevaccinePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lymphoma, Low-Grade cohort.

Asset / SponsorPhaseRating
Fludarabine
Massachusetts General Hospital
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Genzyme, a Sanofi Company
Phase 3BB
IBRITUMOMAB TIUXETAN
Bayer
Phase 4BB
Pixantrone
CTI BioPharma
Phase 3B
FILGRASTIM
Massachusetts General Hospital
Phase 2B

View all 17 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →